Laurus Labs invested INR 1.08 billion in KRKA Pharma: what it means for Laurus Labs stock

Published on 10/25/2026 at 01:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A rights issue added 107.8 million shares while Laurus Labs kept 49 percent. Laurus Labs stock faces results on October 29, 2026.

Capital plan and reporting calendar

Laurus Labs invested INR 1.08 billion in KRKA Pharma on October 14, 2026.
First-quarter revenue reached INR 20.26 billion and net profit reached INR 3.68 billion.
The board is scheduled to review second-quarter and first-half results on October 29, 2026.

Laurus, INE947Q01028, Illustration mit AI erstellt.

Laurus Labs (ISIN INE947Q01028) invested INR 1.08 billion in KRKA Pharma through a rights issue on October 14, 2026, acquiring 107.8 million shares while retaining a 49 percent stake. The investment was reported by Tulsian AI.

Three milestones shape the story

On September 18, 2026, Laurus Labs reported first-quarter revenue of INR 20.26 billion, up 29 percent from the prior-year quarter, while net profit rose 126 percent to INR 3.68 billion, according to MillionsHQ. On October 13, 2026, Laurus Labs scheduled a results conference call for October 29, 2026, at 5:00 p.m. IST. The October 14 capital commitment is the latest of the three events.

What does the investment mean?

The rights issue increased Laurus Labs' holding in KRKA Pharma to 262.15 million shares, but its ownership percentage stayed at 49 percent. The structure points to additional funding for the existing joint venture rather than a change in control, as Free Press Journal reported on October 15, 2026.

The operating backdrop was stronger in the first quarter of fiscal year 2027. Revenue reached INR 20.26 billion and EBITDA margin expanded to 31.80 percent, while research and development spending rose to INR 1.18 billion, according to MillionsHQ. The upcoming report will show whether that operating improvement continued into the September quarter.

Two dates are next

The board is scheduled to consider the unaudited second-quarter and first-half results and an interim dividend on October 29, 2026, according to Tulsian AI. The same filing states that the insider trading-window closure is scheduled to end on October 31, 2026, as Tulsian AI reported.

Revenue scale supports the expansion

Laurus Labs generated INR 68.13 billion in revenue during fiscal year 2026 and employed more than 8,126 people, according to its October 13, 2026 filing. The company describes its operations as research-driven pharmaceutical manufacturing spanning active pharmaceutical ingredients, intermediates, generic medicines and contract development and manufacturing services.